Acceleron Pharma (XLRN) Misses Q4 EPS by 36c, Revenues Miss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Misses Q4 EPS by 36c, Revenues Miss

Acceleron Reports Fourth Quarter and Full Year 2020 Financial Results

February 25, 2021 4:01 PM EST

- Updates from ongoing PULSAR and SPECTRA Phase 2 clinical trials of sotatercept in patients with pulmonary arterial hypertension (PAH) presented at the American Heart Association (AHA) 2020 Scientific Sessions -

- STELLAR Phase 3 trial initiated with sotatercept in PAH -

- Acceleron recognized approximately $23.0 million in royalty revenue from approximately $115 million in net sales of REBLOZYL® (luspatercept-aamt) for Q4 2020 and approximately $54.8 million in royalty revenue from approximately $274 million in net sales of REBLOZYL for full year 2020 -

- Multiple clinical presentations on REBLOZYL reviewed... More